Literature DB >> 8327132

The natural history of amyotrophic lateral sclerosis.

S P Ringel1, J R Murphy, M K Alderson, W Bryan, J D England, R G Miller, J H Petajan, S A Smith, R I Roelofs, F Ziter.   

Abstract

Using 42 strength and functional assessments recorded monthly, the natural history of amyotrophic lateral sclerosis (ALS) is described in 167 patients (98 men, 67 women) followed in five medical centers in the western United States. The mean age at onset was 57.4 years, and symptoms were present for 2.64 years before study entry. Although there was a highly variable rate of decline within the group of patients, there were no differences in rate of decline by age or gender. Older patients and women were weaker on entry. Forty-eight patients died during the study. The median survival was 4.0 years for the study cohort but 2.1 years for newly diagnosed cases. Decline in pulmonary function most closely correlated with death. Our results emphasize the importance of considering clinical variability in planning clinical trials. One possible strategy is to identify and stratify patients by rate of decline in pulmonary function since prospectively identifying homogeneous subgroups allows investigators to substantially reduce sample size in therapeutic trials.

Entities:  

Mesh:

Year:  1993        PMID: 8327132     DOI: 10.1212/wnl.43.7.1316

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

Review 1.  Management of motor neurone disease.

Authors:  R S Howard; R W Orrell
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

2.  Prediction of prognosis of ALS: Importance of active denervation findings of the cervical-upper limb area and trunk area.

Authors:  Yoko Sato; Eiji Nakatani; Yasuhiro Watanabe; Masanori Fukushima; Kenji Nakashima; Mari Kannagi; Yasuhiro Kanatani; Hiroshi Mizushima
Journal:  Intractable Rare Dis Res       Date:  2015-11

Review 3.  Amyotrophic lateral sclerosis: current and future treatment strategies.

Authors:  B W Festoff
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Clinical approach to the diagnostic evaluation of hereditary and acquired neuromuscular diseases.

Authors:  Craig M McDonald
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

5.  Respiratory Muscle Strength as a Predictive Biomarker for Survival in Amyotrophic Lateral Sclerosis.

Authors:  Michael I Polkey; Rebecca A Lyall; Ke Yang; Erin Johnson; P Nigel Leigh; John Moxham
Journal:  Am J Respir Crit Care Med       Date:  2017-01-01       Impact factor: 21.405

6.  National Study of Muscle Cramps in ALS in the USA.

Authors:  Helen E Stephens; Nanette C Joyce; Björn Oskarsson
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-12-15       Impact factor: 4.092

7.  Evaluating In Vivo-In Vitro Correlation Using a Bayesian Approach.

Authors:  Junshan Qiu; Marilyn Martinez; Ram Tiwari
Journal:  AAPS J       Date:  2016-02-19       Impact factor: 4.009

8.  Continuous response variable trial design in motor neuron disease: long term treatment with a TRH analogue (RX77368).

Authors:  A Goonetilleke; R J Guiloff
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

9.  Serum uric acid level is associated with the prevalence but not with survival of amyotrophic lateral sclerosis in a Chinese population.

Authors:  Zhenzhen Zheng; Xiaoyan Guo; Qianqian Wei; Wei Song; Bei Cao; Rui Huang; Ruwei Ou; Xueping Chen; Huifang Shang
Journal:  Metab Brain Dis       Date:  2014-03-01       Impact factor: 3.584

Review 10.  Prognostic factors in ALS: A critical review.

Authors:  Adriano Chiò; Giancarlo Logroscino; Orla Hardiman; Robert Swingler; Douglas Mitchell; Ettore Beghi; Bryan G Traynor
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.